Complete Blood Count (CBC)

The Prothrombin gene test is used to assess the genetic risk of abnormal blood clot formation, particularly in individuals with an unexplained history of thrombosis. It also helps guide treatment decisions and management strategies to prevent future thrombotic complications

. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disorder that affects the function of red blood cells. It is caused by mutations in the G6PD gene, leading to reduced or absent activity of the G6PD enzyme, which plays a crucial role in protecting red blood cells from oxidative damage.
. When exposed to certain triggers such as infections, certain medications (e.g., sulfa drugs, antimalarials), or fava beans, affected individuals may develop hemolytic anemia, a condition where red blood cells break down prematurely, causing symptoms like jaundice, fatigue, dark urine, and shortness of breath.
. G6PD deficiency is X-linked, meaning it primarily affects males, while females can be carriers or mildly affected.

. A complete blood count is a test for screening various diseases like anemia, high/low WBCs count, platelets disorders and inflammatory processes.
. The test is performed on cord blood sample in newly born infants.

Evaluate Heparin activity, especially low molecular weight Heparin (LMWH) and unfractionated Heparin (UFH)

A “FLC Kappa + Lambda Quantitative” test measures the levels of both Kappa and Lambda free light chains (FLC) in a blood sample, allowing for the calculation of their ratio, which is used to help diagnose and monitor plasma cell disorders like multiple myeloma and amyloidosis, as an abnormal ratio between the two light chains can indicate a potential problem with plasma cell production